Pages that link to "Q33327237"

The following pages link to In vivo selection of intrabodies specifically targeting protein-protein interactions: a general platform for an "undruggable" class of disease targets (Q33327237):

Displaying 12 items.

• Intracellular activation of interferon regulatory factor-1 by nanobodies to the multifunctional (Mf1) domain (Q24634375) (← links)
• Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm? (Q26738467) (← links)
• Specific in vivo knockdown of protein function by intrabodies (Q26801077) (← links)
• A llama-derived gelsolin single-domain antibody blocks gelsolin-G-actin interaction (Q27659637) (← links)
• A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain (Q27660385) (← links)
• Engineering antibody fragments to fold in the absence of disulfide bonds (Q33403805) (← links)
• Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease (Q36108119) (← links)
• A novel intracellular antibody against the E6 oncoprotein impairs growth of human papillomavirus 16-positive tumor cells in mouse models (Q37085816) (← links)
• Therapeutic antibodies: successes, limitations and hopes for the future (Q37491236) (← links)
• New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics (Q38289992) (← links)
• Intracellular antibodies and cancer: new technologies offer therapeutic opportunities (Q39864280) (← links)
• Antibody-enabled small-molecule drug discovery (Q84489672) (← links)